Biomarker analysis and final results of INT70/09 phase II proof-of-concept study of pazopanib (PZP) in refractory urothelial cancer (UC).
Andrea Necchi
Consultant or Advisory Role - GlaxoSmithKline
Nadia Zaffaroni
No relevant relationships to disclose
Luigi Mariani
No relevant relationships to disclose
Lawrence H. Schwartz
No relevant relationships to disclose
Nicola Nicolai
No relevant relationships to disclose
Patrizia Giannatempo
No relevant relationships to disclose
Flavio Crippa
No relevant relationships to disclose
Carlo Morosi
No relevant relationships to disclose
Alessandro M. Gianni
No relevant relationships to disclose
Filippo G. De Braud
No relevant relationships to disclose
Roberto Salvioni
No relevant relationships to disclose